Paradoxical SAPHO syndrome observed during anti-TNFα therapy for Crohn’s disease
نویسندگان
چکیده
Currently, anti-TNFα antibodies are used to treat Crohn's disease. We report on a 45-year-old Japanese female with Crohn's disease developing SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome following exposure to the anti-TNFα antibody adalimumab. Initially, adalimumab induced remission, but the patient showed SAPHO syndrome 11 weeks following the start of adalimumab therapy for the first time. Cutaneous and articular involvement were exacerbating the condition, so adalimumab was discontinued and the patient was put on low-dose methotrexate to control her symptoms. To our knowledge, this is the first report of SAPHO syndrome occurring during anti-TNF therapy, which is thought to be a paradoxical response to adalimumab.
منابع مشابه
Psoriatic skin lesions induced by tumor-necrosis-factor-alpha-therapy
A 46-year-old, caucasian woman suffering from Crohn’s disease and a 35-year-old woman suffering from ankylosing spondylitis were treated with the TNFα blocker infliximab and developed psoriasiform skin lesions. The pathophysiology of this paradoxical clinical response as a newly recognized adverse effect of TNFα antagonists is unknown. According to the literature, this type of newly triggered p...
متن کاملParadoxical response with increased tumor necrosis factor-α levels to anti-tuberculosis treatment in a patient with disseminated tuberculosis
It has been reported that tuberculosis (TB) worsens after cessation of tumor necrosis factor-α inhibitors and starting anti-TB treatment. Little is known about the immunological pathogenesis of this paradoxical response (PR). We report the first case of a TB patient in whom PR occurred concurrently with elevation of circulating tumor necrosis factor-α (TNFα) levels. A 75-year-old woman, who had...
متن کاملPatient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn’s Disease
Treatment with Anti-Tumor Necrosis Factor (anti-TNF) therapy has become a mainstay of therapy for patients with CD who are unresponsive to conventional medical management. Currently there are three anti-TNFα antibodies that have been approved by the US Food and Drug Administration for the treatment of CD, namely infliximab, adalimumab and certolizumab pegol (CZP). Several double blind placebo c...
متن کاملSequential Combination Therapy Leading to Sustained Remission in a Patient with SAPHO Syndrome
The SAPHO syndrome represents a variety of clinically similar disorders with the key features of hyperostotic bone lesions in combination with chronic pustular skin disease. The respective pathophysiology of bone and joint manifestations in SAPHO syndrome is still a matter of discussion. For example it does not appear to represent reactive arthritis and HLA B27 antigen, with the latter being ty...
متن کاملPediatric Treatment-Resistant Nonbacterial Osteomyelitis of the Mandible Associated with SAPHO Syndrome
SAPHO syndrome is a chronic disease of unknown etiology, which is characterized by synovitis, acne, pustulosis, hyperostosis, and osteitis, however, pediatric osteomyelitis of the jawbone is rarely reported. We present a report of pediatric nonbacterial osteomyelitis of the mandible associated with SAPHO syndrome. A seven-year-old girl presented complaining of pain in, and swelling of, the righ...
متن کامل